Literature DB >> 24131165

Clinician beliefs and attitudes about buprenorphine/naloxone diversion.

Zev Schuman-Olivier1, Hilary Connery, Margaret L Griffin, Steve A Wyatt, Alan A Wartenberg, Jacob Borodovsky, John A Renner, Roger D Weiss.   

Abstract

BACKGROUND AND OBJECTIVES: Concern about diversion of buprenorphine/naloxone (B/N) in the United States may affect prescribing patterns and policy decisions. This study examines addiction treatment clinician beliefs and attitudes regarding B/N diversion.
METHODS: Participants (n = 369) completed a 34-item survey in 2010 during two national symposia on opioid dependence. We conducted multivariable regression, examining the relationship of perceived danger from B/N diversion with clinician characteristics and their beliefs about B/N treatment and diversion. We compared causal beliefs about diversion among clinicians with and without B/N treatment experience.
RESULTS: Forty percent of clinicians believed that B/N diversion is a dangerous problem. The belief that B/N diversion increases accidental overdoses in the community was strongly associated with perceived danger from B/N diversion. CONCLUSIONS AND SCIENTIFIC SIGNIFICANCE: Attitudes and beliefs, not education level, were associated with clinician's perceived danger from B/N diversion. Clinicians with greater B/N patient experience were more likely to believe treatment access barriers are the major cause of B/N diversion.
Copyright © American Academy of Addiction Psychiatry.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24131165      PMCID: PMC3801272          DOI: 10.1111/j.1521-0391.2013.12024.x

Source DB:  PubMed          Journal:  Am J Addict        ISSN: 1055-0496


  31 in total

1.  Six deaths linked to misuse of buprenorphine-benzodiazepine combinations.

Authors:  M Reynaud; A Tracqui; G Petit; D Potard; P Courty
Journal:  Am J Psychiatry       Date:  1998-03       Impact factor: 18.112

2.  Adverse effects in children after unintentional buprenorphine exposure.

Authors:  Ann-Jeannette Geib; Kavita Babu; Michele Burns Ewald; Edward W Boyer
Journal:  Pediatrics       Date:  2006-10       Impact factor: 7.124

3.  A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network.

Authors:  Walter Ling; Leslie Amass; Steve Shoptaw; Jeffrey J Annon; Maureen Hillhouse; Dean Babcock; Greg Brigham; Judy Harrer; Malcolm Reid; Joan Muir; Betty Buchan; Debbie Orr; George Woody; Jonathan Krejci; Douglas Ziedonis
Journal:  Addiction       Date:  2005-08       Impact factor: 6.526

4.  Inability to access buprenorphine treatment as a risk factor for using diverted buprenorphine.

Authors:  Michelle R Lofwall; Jennifer R Havens
Journal:  Drug Alcohol Depend       Date:  2012-06-15       Impact factor: 4.492

5.  Client and counselor attitudes toward the use of medications for treatment of opioid dependence.

Authors:  Traci Rieckmann; Marilyn Daley; Bret E Fuller; Cindy P Thomas; Dennis McCarty
Journal:  J Subst Abuse Treat       Date:  2006-12-08

6.  Buprenorphine/naloxone reduces the reinforcing and subjective effects of heroin in heroin-dependent volunteers.

Authors:  Sandra D Comer; Ellen A Walker; Eric D Collins
Journal:  Psychopharmacology (Berl)       Date:  2005-09-29       Impact factor: 4.530

7.  Suboxone (buprenorphine/naloxone) toxicity in pediatric patients: a case report.

Authors:  Kerry A Schwarz; F Lee Cantrell; Rais B Vohra; Richard F Clark
Journal:  Pediatr Emerg Care       Date:  2007-09       Impact factor: 1.454

Review 8.  Safety and health policy considerations related to the use of buprenorphine/naloxone as an office-based treatment for opiate dependence.

Authors:  T Peter Bridge; Paul J Fudala; Susan Herbert; Deborah B Leiderman
Journal:  Drug Alcohol Depend       Date:  2003-05-21       Impact factor: 4.492

9.  Use and misuse of buprenorphine in the management of opioid addiction.

Authors:  Theodore J Cicero; Hilary L Surratt; James Inciardi
Journal:  J Opioid Manag       Date:  2007 Nov-Dec

10.  Buprenorphine misuse among heroin and amphetamine users in Malmo, Sweden: purpose of misuse and route of administration.

Authors:  A Hakansson; A Medvedeo; M Andersson; M Berglund
Journal:  Eur Addict Res       Date:  2007       Impact factor: 3.015

View more
  15 in total

1.  Practice Guidance for Buprenorphine for the Treatment of Opioid Use Disorders: Results of an Expert Panel Process.

Authors:  Carrie M Farmer; Dawn Lindsay; Jessica Williams; Amanda Ayers; James Schuster; Alyssa Cilia; Michael T Flaherty; Todd Mandell; Adam J Gordon; Bradley D Stein
Journal:  Subst Abus       Date:  2015-04-06       Impact factor: 3.716

2.  Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.

Authors:  Kelly E Dunn; D Andrew Tompkins; George E Bigelow; Eric C Strain
Journal:  JAMA Psychiatry       Date:  2017-09-01       Impact factor: 21.596

3.  Perceptions and practices addressing diversion among US buprenorphine prescribers.

Authors:  Lewei Allison Lin; Michelle R Lofwall; Sharon L Walsh; Adam J Gordon; Hannah K Knudsen
Journal:  Drug Alcohol Depend       Date:  2018-03-10       Impact factor: 4.492

4.  Organizational Facilitators and Barriers to Medication for Opioid Use Disorder Capacity Expansion and Use.

Authors:  Nora Jacobson; Julie Horst; Liam Wilcox-Warren; Alex Toy; Hannah K Knudsen; Randy Brown; Eric Haram; Lynn Madden; Todd Molfenter
Journal:  J Behav Health Serv Res       Date:  2020-10       Impact factor: 1.505

5.  A systematic review of patients' and providers' perspectives of medications for treatment of opioid use disorder.

Authors:  Katharine Cioe; Breanne E Biondi; Rebecca Easly; Amanda Simard; Xiao Zheng; Sandra A Springer
Journal:  J Subst Abuse Treat       Date:  2020-09-22

6.  Interprofessional prescription opioid abuse communication among prescribers and pharmacists: A qualitative analysis.

Authors:  Nicholas E Hagemeier; Fred Tudiver; Scott Brewster; Elizabeth J Hagy; Brittany Ratliff; Angela Hagaman; Robert P Pack
Journal:  Subst Abus       Date:  2017-09-15       Impact factor: 3.716

7.  Video directly observed therapy for patients receiving office-based buprenorphine - A pilot randomized controlled trial.

Authors:  Judith I Tsui; Brian G Leroux; Andrea C Radick; Zachery A Schramm; Kendra Blalock; Colleen Labelle; Matthew Heerema; Jared W Klein; Joseph O Merrill; Andrew J Saxon; Jeffrey H Samet; Theresa W Kim
Journal:  Drug Alcohol Depend       Date:  2021-07-28       Impact factor: 4.852

8.  "You are not clean until you're not on anything": Perceptions of medication-assisted treatment in rural Appalachia.

Authors:  Emma L Richard; Christine A Schalkoff; Hannah M Piscalko; Daniel L Brook; Adams L Sibley; Kathryn E Lancaster; William C Miller; Vivian F Go
Journal:  Int J Drug Policy       Date:  2020-03-12

9.  Illicit buprenorphine use, interest in and access to buprenorphine treatment among syringe exchange participants.

Authors:  Aaron D Fox; Adam Chamberlain; Nancy L Sohler; Taeko Frost; Chinazo O Cunningham
Journal:  J Subst Abuse Treat       Date:  2014-08-07

10.  Prevalence and treatment of opioid use disorders among primary care patients in six health systems.

Authors:  Gwen Lapham; Denise M Boudreau; Eric A Johnson; Jennifer F Bobb; Abigail G Matthews; Jennifer McCormack; David Liu; Jeffrey H Samet; Andrew J Saxon; Cynthia I Campbell; Joseph E Glass; Rebecca C Rossom; Mark T Murphy; Ingrid A Binswanger; Bobbi Jo H Yarborough; Katharine A Bradley
Journal:  Drug Alcohol Depend       Date:  2019-11-15       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.